Dipna PharmachemShare price, financial results, shareholding and management

BSE SME · DPLPharmaceuticals & Biotechnology
dipnapharmachem.com ↗Live price on BSE ↗ISIN INE0MC401013 · Lot 3,000 shares · ₹12,420
₹4.14
+3.20% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹11 cr
Stock P/E
4.1peers 23.8
Book value
₹23.6
Price to book
0.18
EV / operating profit
-
Market cap to sales
0.08
Returns and growth
ROCE · FY26
7.7%
ROE · FY26
5.3%
ROE, 3-year average
3.8%
Operating margin · FY26
3.9%peers 16.5%
Sales growth, 3 years
8.9%
Profit growth, 3 years
42.4%
Safety
Debt to equity
0.21peers 0.48
Borrowings
₹13 cr
Interest cover
3.4×
Cash from business / op. profit
-360%
Debtor days
136
Pledged
0.00%
Ownership and share
Promoter holding
9.13%
Change in promoter holding
0.00 pts
Shareholders
1,788
52-week high / low
₹19 / ₹4
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.

Dipna Pharmachem share price chart

₹4.14-75.96% 1 year

Close on 19 Nov 2026 · +3.24% on the day · Vol 90,000

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+2.0%
3 months
-31.6%
6 months
-48.6%
1 year
-76.0%
Traded a day, 20 days
₹0.01 cr

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+3%+171%
3 years, a year+9%+42%
Latest half, H1 FY26-20%+315%

Dipna Pharmachem revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown steadily. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150200Sales, FY18: 17 ₹ cr17Net profit, FY18: 0 ₹ cr0FY18Sales, FY19: 20 ₹ cr20Net profit, FY19: 0 ₹ cr0FY19Sales, FY20: 30 ₹ cr30Net profit, FY20: 0 ₹ cr0FY20Sales, FY21: 31 ₹ cr31Net profit, FY21: 0 ₹ cr0FY21Sales, FY22: 73 ₹ cr73Net profit, FY22: 1 ₹ cr1FY22Sales, FY23: 99.9 ₹ cr99.9Net profit, FY23: 0.9 ₹ cr0.9FY23Sales, FY24: 164 ₹ cr164Net profit, FY24: 1.1 ₹ cr1.1FY24Sales, FY25: 125 ₹ cr125Net profit, FY25: 1 ₹ cr1FY25Sales, FY26: 129 ₹ cr129Net profit, FY26: 2.6 ₹ cr2.6FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H1FY23: 48.6 ₹ cr48.6Net profit, H1FY23: 0.3 ₹ cr0.3H1FY23Sales, H2FY23: 51.3 ₹ cr51.3Net profit, H2FY23: 0.6 ₹ cr0.6H2FY23Sales, H1FY24: 74 ₹ cr74Net profit, H1FY24: 0.6 ₹ cr0.6H1FY24Sales, H2FY24: 90.3 ₹ cr90.3Net profit, H2FY24: 0.5 ₹ cr0.5H2FY24Sales, H1FY25: 90.6 ₹ cr90.6Net profit, H1FY25: 0.3 ₹ cr0.3H1FY25Sales, H2FY25: 34.3 ₹ cr34.3Net profit, H2FY25: 0.6 ₹ cr0.6H2FY25Sales, H1FY26: 72.3 ₹ cr72.3Net profit, H1FY26: 1.4 ₹ cr1.4H1FY26

SME companies report every six months. In the latest half, sales were lower than in the same half a year before. Profit grew faster than sales.

Dipna Pharmachem half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY23H2FY23H1FY24H2FY24H1FY25H2FY25H1FY26
Sales48.6051.3274.0390.3190.6234.2972.33
Expenses47.7049.8972.5188.4089.1532.3370.63
Operating profit0.911.441.521.901.481.961.70
OPM1.9%2.8%2.1%2.1%1.6%5.7%2.4%
Interest0.450.510.871.131.0211
Depreciation00.010.010.0100.010.01
Profit before tax0.450.930.800.620.460.961.91
Net profit0.330.580.590.490.340.641.41

Dipna Pharmachem profit and loss

Full years to March, FY18 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Sales172030317399.93164.34124.92129.08
Expenses162030317197.58160.91121.48124.09
Operating profit000022.343.433.435
OPM2.4%2.4%1.5%1.3%3.0%2.3%2.1%2.8%3.9%
Other income000000.0100.010.03
Interest000010.9622.021.46
Depreciation000000.010.020.010.01
Exceptional and other items····1····
Profit before tax000021.381.421.423.54
Tax rate14.0%40.0%0.0%60.0%50.0%34.1%23.9%31.7%25.7%
Net profit000010.911.080.972.63
EPS ₹63621170.760.900.41·
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

The years to FY22 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Earnings per share is left blank where the source shows zero against a profit.

Earnings per share before FY22 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.

Dipna Pharmachem profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a low return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%2%4%6%FY18: 2.4%2.4%FY18FY19: 2.4%2.4%FY19FY20: 1.5%1.5%FY20FY21: 1.3%1.3%FY21FY22: 3.0%3.0%FY22FY23: 2.3%2.3%FY23FY24: 2.1%2.1%FY24FY25: 2.8%2.8%FY25FY26: 3.9%3.9%FY26
Per cent
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Operating margin2.4%2.4%1.5%1.3%3.0%2.3%2.1%2.8%3.9%
Tax rate14.0%40.0%0.0%60.0%50.0%34.1%23.9%31.7%25.7%
ROCE·0.0%0.0%0.0%23.9%9.0%7.1%6.2%7.7%
ROE·0.0%0.0%0.0%64.9%7.0%3.5%2.6%5.3%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Dipna Pharmachem debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
020406080Net worth, FY18: 0 ₹ cr0Borrowings, FY18: 5 ₹ cr5FY18Net worth, FY19: 0 ₹ cr0Borrowings, FY19: 6 ₹ cr6FY19Net worth, FY20: 1 ₹ cr1Borrowings, FY20: 10 ₹ cr10FY20Net worth, FY21: 1 ₹ cr1Borrowings, FY21: 12 ₹ cr12FY21Net worth, FY22: 2 ₹ cr2Borrowings, FY22: 10 ₹ cr10FY22Net worth, FY23: 24 ₹ cr24Borrowings, FY23: 16 ₹ cr16FY23Net worth, FY24: 37 ₹ cr37Borrowings, FY24: 19 ₹ cr19FY24Net worth, FY25: 38 ₹ cr38Borrowings, FY25: 17 ₹ cr17FY25Net worth, FY26: 62 ₹ cr62Borrowings, FY26: 13 ₹ cr13FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-30-20-10010Net profit, FY18: 0 ₹ cr0FY18Net profit, FY19: 0 ₹ cr0FY19Cash from the business, FY20: -3 ₹ cr-3Net profit, FY20: 0 ₹ cr0FY20Cash from the business, FY21: -2 ₹ cr-2Net profit, FY21: 0 ₹ cr0FY21Cash from the business, FY22: 3 ₹ cr3Net profit, FY22: 1 ₹ cr1FY22Cash from the business, FY23: -21 ₹ cr-21Net profit, FY23: 0.9 ₹ cr0.9FY23Cash from the business, FY24: -5 ₹ cr-5Net profit, FY24: 1.1 ₹ cr1.1FY24Cash from the business, FY25: -9 ₹ cr-9Net profit, FY25: 1 ₹ cr1FY25Cash from the business, FY26: -18 ₹ cr-18Net profit, FY26: 2.6 ₹ cr2.6FY26

Bars below the line are cash going out.

Dipna Pharmachem balance sheet

At each 31 March · ₹ crore

₹ crore
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Equity capital0.040.040.040.040.0412242426
Reserves0011212131436
Net worth0.040.041.041.042.0424373862
Borrowings5610121016191713
Other liabilities5.967.966.9611.9623.96387777131
Total liabilities111418253678133132206
Fixed assets000000000
Capital work in progress000000000
Investments000000000
Other assets111418253678133132206

Dipna Pharmachem cash flow

₹ crore

₹ crore
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Cash from operations··-3-23-21-5-9-18
Cash from investing··0000000
Cash from financing··32-32614-419
Net cash flow··00059-131

Working capital

Days

Days
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Debtor days13216013417613510469135136
Inventory days11266708934728688144
Days payable142148105145123139172243375
Cash conversion cycle10378991204638-17-20-95
Working capital days364447371088013756

Dipna Pharmachem peers and competitors

Listed SME companies in the same industry

By sales, Dipna Pharmachem is number 10 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem114.11292.63.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Sotac Pharmaceuticals10017.31015.817.7%0.64
Accretion Pharmaceuticals21522.289.69.716.7%0.23
Median of the 10 others18523.8123816.5%0.48

Dipna Pharmachem shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own less than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.

Promoters
9.13%
-48.06 pts since Sep 23
Number of shareholders
1,788
1,078 in Sep 23

Dipna Pharmachem shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 23Mar 24Sep 24Mar 25Sep 25Nov 25Mar 26Jun 26
Promoters57.19%9.98%9.98%9.98%9.98%9.13%9.13%9.13%
Number of shareholders1,0781,8072,6521,9971,7421,7411,7171,788

Dipna Pharmachem latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H1 FY26: sales ₹72.3 cr (-20%), net profit ₹1.4 cr (+315%) on H1 FY25.
  • Shareholding, 30 June 2026: promoters unchanged at 9.13%.

Dipna Pharmachem announcements

1 on record, latest first; each opens the filing on the exchange

Dipna Pharmachem annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Dipna Pharmachem share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Dipna Pharmachem's data · 7

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (2,62,89,250 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • !Earnings per share changes basis between FY22 (₹117.00) and FY23 (₹0.76) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY18 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Dipna Pharmachem

What does Dipna Pharmachem do?

Dipna Pharmachem is an SME company listed on BSE SME, in pharmaceuticals & biotechnology.

What is the share price of Dipna Pharmachem?

₹4.1 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Dipna Pharmachem?

₹11 cr at the close on 19 Nov 2026, on 2,62,89,250 shares.

What is the P/E of Dipna Pharmachem?

4.1 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Dipna Pharmachem's revenue and profit?

Revenue ₹129 cr and profit after tax ₹3 cr in FY26.

Who are the promoters of Dipna Pharmachem?

The promoter group; promoters held 9.13% at 30 June 2026.

What is Dipna Pharmachem's website?

www.dipnapharmachem.com

More SME companies like Dipna Pharmachem

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology →

Built from 1 exchange announcements, 8 shareholding patterns and 9 years of reported results. Every figure carries its source; where the documents are silent, the page says so.